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Aim An implantable loop recorder (ILR) is indicated in patients with unexplained syncope after complete conventional
work-up. Data from the literature imply that, in clinical practice, the ILR is underused. The aim of the study was
to verify if there is any discrepancy between the use of ILRs in clinical practice and the potential indications based
on the most potentially appropriate guideline indications.
Method and
results
We compared the prevalence of ILRs actually implanted in patients with unexplained syncope in the Syncope Unit
Project (SUP) study and the potential one using the standard given by the guidelines. In the SUP study, 28 (18%) out
of 159 patients with unexplained syncope received an ILR. Appropriate criteria for implantation of ILRs according to
guidelines were present in 110 (69%) patients. Moreover, 7 (25%) of ILRs actually implanted did not satisfy the guide-
line standards. During the follow-up, 32% of patients who had received an ILR had a diagnosis compared with 5% of
those who did not (P ¼ 0.001).
Conclusions The estimated indications were four times higher than those observed. Moreover, in about one quarter of the cases,
the use of ILRs proved to be potentially inappropriate according to guideline indications. Two-thirds of patients with
unexplained syncope had indications potentially appropriate for ILRs.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
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Introduction
Despite recent advances in diagnostic procedures, syncope remains
unexplainedin17–37%ofpatients.
1Eveninspecializedsyncopefacili-
ties,therateofunexplainedsyncopeis,withafewexceptions,around
18–20%.
1 Thus, the present strategy of management cannot be con-
sidered satisfactory. Implantable loop recorders (ILRs) are indicated
in patients with unexplained syncope after a complete conventional
work-up.
1 Currently, the prevalence of using ILRs in the real-world
is unknown for patients with unexplained syncope. Solano et al.
2
have estimated that 5% of all patients referred to two tertiary
centres for the evaluation of syncope and 28% of those with unex-
plained syncope had received an ILR after complete work-up. In
the Evaluation of Guidelines in Syncope Study 2,
3 of 269 patients
referred to Emergency Department, only 1% received an ILR.
We assumed that ILRs are still underused in everyday clinical
practice. As a consequence, we have studied patients in the
Syncope Unit Project (SUP)
4 who still remained with a diagnosis
†The Syncope Unit Project (SUP) investigators are listed in the Appendix.
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The aim of our study was to conﬁrm if there is a discrepancy
between the use of ILRs in everyday clinical practice and their
potential for greater use. The indications were based on the appli-
cation of restricted criteria from the recently published position
paper of the European Heart Rhythm Association (EHRA)
5 and
the guidelines on syncope of the European society of Cardiology
(ESC).
1
Method
In the multicentre, prospective, and observational SUP study,
4 the
real-world practice of nine Italian hospitals equipped with Syncope
Units was documented. In brief, physicians of the nine Syncope
Units applied the diagnostic-therapeutic pathway protocol for diag-
nosis and treatment of syncope from ESC guidelines and were sup-
ported by software called ‘Syncope web’.
4 Consecutive patients,
referred from 15 March to 15 September 2008 were included.
Of the 700 patients who underwent investigations to identify the
nature of loss of consciousness, a diagnosis was established in
541 patients at the end of full conventional work-up and remained
unexplained in 159 patients. These patients with unexplained
syncope constitute the population of the present study and, at
this point, started clinical follow-up. Follow-up data were collected
in autumn 2009.
We compared the prevalence of ILRs actually implanted (indi-
cated by the physician investigator) and that estimated using
restricted criteria based on Class I recommendations of the
recently published EHRA
5 and ESC guidelines.
1 The implant of
an ILR was considered appropriate when the patient had one of
these characteristics:
(i) unexplained syncope and structural heart disease or coronary
artery disease,
(ii) unexplained syncope in patients with bundle branch block,
and
(iii) unexplained syncope in patients with absence of signiﬁcant
structural heart disease, age ≥40, and three or more episodes
of syncope during the last 2 years.
These criteria are more restrictive than those of Class I of EHRA
5
and ESC guidelines
1 because, in contrast, patients without cardiac
disease were included only if they had had three or more episodes
of syncope in the previous 2 years and age ≥40 years.
Moreover, we calculated the number of ILRs which did not meet
the previously mentioned requirements, and were thus considered
inappropriate indications.
For all other inclusion and exclusion criteria, reference to the
SUP
4 study should be made. Data were reported as mean+1
standard deviation or as median with inter-quartile range as
appropriate. Comparison between actual observed and esti-
mated indications for ILRs was performed by means of cross-
tabulation and Kappa statistics for measurements of agreement
between indications according to physician practice and guide-
lines. Comparison between two continuous variables, which
had a non-Gaussian distribution, was performed by applying
the Mann–Whitney non-parametric test. Comparison between
proportions was made by means of the Fisher’s exact test.
Results
The clinical data of the 159 patients with unexplained syncope are
shown in Table 1; 28 received an ILR and 131 did not. There were
no signiﬁcant differences between those who received an ILR and
those who did not.
Appropriate criteria for implantation of an ILR (as established by
our method) were present in 110 (69%) patients. In contrast, ILRs
had been actually implanted in 28 (18%) patients, P , 0.0001 vs.
estimated criteria (Table 2 and Figure 1). Consequently, there
was a high discrepancy between observed and estimated indi-
cations [kappa test ¼ 0.03 (CI 20.06 to 0.10)]. Thus, the esti-
mated indications were four times higher than those observed:
110 (16%) vs. 28 (4%) of all 700 patients who had undergone
a full conventional diagnostic work-up, which corresponds to
69 vs. 18% of the 159 patients with unexplained syncope.
Among the 110 patients with potential indications for an ILR,
56 belonged to the subgroup with structural or coronary heart
................................................................................
Table 1 Characteristics of the 131 patients with
unexplained syncope who did not receive an ILR and
of those 28 who did
No ILR
(n 5 131)
ILR
(n 5 28)
P
-value
Median age (inter-quartile range) 73 (65–80) 70 (61–75) 0.90
Male gender (%) 81 (62) 17 (61) 0.90
History of T-LOCs:
First episode (%) 33 (25) 3 (11) 0.17
Recurrent T-LOCs, n (%) 98 (75) 25 (89) 0.17
median number
(inter-quartile range)
3 (2–6) 4 (3–6) 0.11
duration (years;
inter-quartile range)
2 (1–5) 4 (1–5) 0.58
No warning at the onset of the
attack (%)
55 (42) 14 (50) 0.57
Structural heart disease (%) 68 (52) 8 (28) 0.36
coronary artery disease (%) 33 (25) 6 (21) 0.84
hypertensive
cardiopathy (%)
13 (10) 1 (4) 0.52
valvular (%) 7 (5) 1 (4) 0.79
others (%) 15 (11) 0 (0) 0.14
Electrocardiographic
abnormalities (%)
66 (50) 9 (32) 0.13
sinus bradycardia
,50 b.p.m. (%)
14 (11) 0 (0) 0.14
bundle branch block (%) 34 (27) 7 (25) 0.13
ST-T abnormalities and/or
ischaemia (%)
9 (7) 1 (4) 0.14
atrial ﬁbrillation/ﬂutter (%) 9 (7) 1 (4) 0.98
OESIL risk score, median
(inter-quartile range)
6
3 (1–3) 2 (1–3) 0.87
EGSYS risk score, median
(inter-quartile range)
7
2 (0–3) 1 (0–3) 0.14
T-LOC, transient loss of consciousness; OESIL, Osservatorio Epidemiologico sulla
Sincope nel Lazio; EGSYS, Evaluation of Guidelines in Syncope Study.
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structural heart disease, and 43 to that of recurrent syncope
without structural heart disease. The prevalence of ILRs actually
implanted in these three subgroups was 8 (14%), 4 (36%), and 9
(21%), respectively. Finally, the remaining seven (25%) implanted
patients had potentially inappropriate ILR indication. They
belonged to the group with recurrent syncope without structural
heart disease: ﬁve of these had no structural heart disease and
less than three syncopal episodes during the last 2 years and
two had no structural heart disease and age ,40 years.
During the subsequent follow-up period, 32% of patients who
had received an ILR had a diagnosis compared with 5% of those
who did not: odds ratio 8.7 (CI 2.9–26.5), P ¼ 0.001 (Table 3).
As a consequence, more ILR patients ﬁnally received a therapy.
Speciﬁcally, a cardiac pacemaker was implanted in 25% of ILR
patients vs. 8% of those who did not receive an ILR (P ¼ 0.02).
Discussion
The most important conclusion of this study is that there is a dis-
crepancy between clinical practice and standardized indications for
ILRs in patients with unexplained syncope. Apparently, there were
no major clinical differences between those who received an ILR
and those who did not. The estimated indications were four
times more than those observed. In addition, in about one
quarter of cases, the use of ILRs proved likely to be inappropriate.
Inappropriate indications were observed in patients with recurrent
syncope without structural cardiac disease or coronary artery
disease.
The follow-up data of the present study conﬁrm the diagnostic
usefulness of an ILR strategy (Table 3). Indeed, without ILRs, the
electrocardiogram (ECG) documentation of a spontaneous
syncope was very unlikely during the subsequent year of follow-up,
and a presumed diagnosis based on new positive ﬁndings of tests
that were initially negative could be made in only 5% of cases. Con-
versely, the ILR strategy allowed 8.7 higher likelihood of ECG diag-
nosis, which was bradyarrhythmic in most of the cases. As a
consequence, speciﬁc therapy could be prescribed in a higher per-
centage of patients.
According to the criteria used in this study, made in accordance
with Class I indications of the recent EHRA and ESC guidelines,
1,5
two-thirds of patients with unexplained syncope had indications
potentially appropriate for ILRs. These indications are justiﬁed,
on one hand, by the high risk of life-threatening arrhythmias in
patients with structural or coronary heart diseases or bundle
branch block and, on the other hand, by the need to prevent
cases of potentially traumatic syncopal relapses. Although it is
well known that structural cardiac disease is itself the most
Figure 1 Flow diagram of the patients evaluated for syncope.
ILR, implantable loop recorder; LR, loop recorder.
................................................................................
Table 2 Relationship between observed and estimated
implantable loop recorder indications
Total patients with
unexplained syncope
(n 5 159)
ILR implanted
(observed)
(n 5 28)
ILR not
implanted
(observed)
(n 5 131)
ILR potentially indicated
(estimated)(n ¼ 110)
21 89
ILR not indicated
(n ¼ 49)
74 2
................................................................................
Table 3 Follow-up results
No ILR
(n 5 131)
ILR
(n 5 28)
P
-value
Follow-up length (days) 385+175 360+221 0.5
Death (%) 6 (5) 1 (4) 0.6
Syncopal recurrence
patients (%) 18 (15) 6 (21) 0.2
ECG documentation (%) 1 (1) 6 (21) 0.001
Other symptomatic
ECG-documented events (%)
0 (0) 3 (11) 0.005
Total diagnoses, n (%) 6 (5) 9 (32) 0.001
long asystolic pauses 6
Severe bradycardia 1
a 2
Carotid sinus syndrome 2
Ventricular tachycardia 1
a
Rapid atrial ﬁbrillation 1
a
Cadioinhibitory vasovagal
syncope (tilt testing)
1
Psychogenic pseudosyncope 1
Time to diagnosis (days) 157+122 110+129 0.07
Cardiac pacing, n (%) 11 (8) 7 (25) 0.02
ECG-guided cardiac pacing
(diagnosis)
36
Empirical cardiac pacing (no
diagnosis)
8
Implantable deﬁbrillator (%) 1 (1) 0 (0) 0.8
ILR after syncopal recurrence (%) 3 (2) –
aDiagnosed by Holter monitoring.
Discrepancy of ILR indications 1477important negative predictor of unfavourable outcomes,
1,8 para-
doxically the most important discrepancy with clinical practice
was observed in the patients with unexplained syncope and conco-
mitant heart disease who received an ILR only in 14% of cases.
Our follow-up data are in line with those reported in the litera-
ture. Several previous studies have shown the usefulness of ILRs in
discovering the arrhythmic cause of unexplained syncope, so
leading to a speciﬁc therapy. Indeed, several studies
9–16 have
thoroughly documented that the ILR is able to provide a corre-
lation between syncope and ECG ﬁndings in 34% of cases (265
of 787 patients). In particular, in patients with unexplained
syncope and presence of moderate structural heart disease
(deﬁned as ejection fraction .35% and negative electrophysiologi-
cal study), Krahn et al.
17 and Menozzi et al.
10 have shown that the
mechanism of syncope is heterogeneous, thus justifying the need
for a precise diagnosis. In patients with syncope, bundle branch
block, and negative electrophysiological study, ILRs were reliable
in correlating the syncopal relapse and abnormal ECG in 37% of
cases, two-thirds of these being caused by prolonged asystole
due to paroxysmal atrioventricular block.
11 In the patients with
recurrent syncope, some studies
9,12,14 showed that ILRs had a diag-
nostic yield ranging between 29 and 69% with a high percentage of
cases having a rather homogeneous mechanism, i.e. a cardioinhibi-
tory vasovagal reﬂex (bradycardia and or sinus arrest). Finally,
about a quarter of the ILR patients beneﬁted from ILR-guided
speciﬁc therapy, the most frequent being cardiac pacing.
2,9–11,18,19
In our study, we analysed only the indication for the patients
with unexplained syncope because there is more scientiﬁc evi-
dence for this. However, there are other indications for implan-
tation of an ILR even if less well established. The International
Study on Syncope of Uncertain Etiology 2
12 showed the usefulness
of ILRs in patients aged .40 years with suspected neurally
mediated syncope and three or more episodes of syncope. In
fact, of 392 patients enrolled in this study, 106 (33%) had docu-
mentation of syncopal relapse within a median of 3 months from
ILR implantation. Of these latter patients, 106 (51%) beneﬁted
by ILR-guided speciﬁc therapy, especially cardiac pacing. During
the subsequent 9 months of follow-up, syncope recurred in 11%
of patients who had received ILR-guided speciﬁc therapy and in
35% of patients who did not. Based on this study, the recent
EHRA position paper ranks asystolic recurrent neurally mediated
syncope as Class IIA indication for an ILR.
5 If this recommendation
is applied to patients in the present database,
4 of 433 patients with
diagnosis of reﬂex syncope or probably reﬂex syncope, a further
28 (5%) patients will have appropriate criteria for implantation of
ILRs.
Finally, this study was not in a position to calculate the other
indications for ILRs, for example, those for differential diagnosis
between syncope and epilepsy
20,21 or syncope and non-accidental
falls in older patients.
22
Incidence
Assuming a population of the referral districts of the nine Syncope
Units of 1 870 000 inhabitants
4 the observed incidence of
implanted ILRs is 30 per million inhabitants per year (CI 23–39),
a ﬁgure which is very similar to that of 34 per million inhabitants
per year calculated by Solano et al.
2 in patients with unexplained
syncope. These ﬁgures seem, therefore, to be representative of
real-world practice in Italy. On the contrary, the estimated inci-
dence according to our predeﬁned criteria (based on Class I indi-
cations of the EHRA and ESC guidelines
1,5) is 118 ILRs per million
inhabitants per year (CI 103–134). How much of the dissemina-
tion of the guidelines will be able to close the gap between the
observed and estimated incidence is a matter of future studies.
In addition, we have calculated the estimated incidence accord-
ing to Class IIA indications of the above guidelines, i.e. in patients
with suspected or certain neurally mediated syncope, assuming
as appropriate the ILR implantation in patients with three or
more recurrent syncopal episodes during the last 2 years with an
absence of a prodrome. The resulting ﬁgure is further 23 ILRs
per million inhabitants per year (CI 17–31). Thus, the total esti-
mated incidence for Class I and IIA indications is 143 per million
inhabitants per year (CI 126–161).
Study limitation
The main and obvious limitation of this study is that its results were
a theoretical estimate of appropriate tests done by means of cross-
sectional analysis of a database. For this reason, they are probably
inaccurate. Only the systematic application of appropriate criteria
in a future prospective study will be able to evaluate the real
impact of ILRs in clinical practice. The incidence values should be
considered purely indicative as several uncontrolled factors may
affect its calculation, such as the small sample size and the potential
selection bias of the patients referred to the Syncope Units. The
high conﬁdence interval of our estimation has important impli-
cations. Although supported by several studies in the literature
and by the recent recommendations of EHRA and ESC guide-
lines,
1,5 the criteria for ILRs examined in this study remain arbitrary
and might not be universally accepted. Nevertheless, this study, to
our knowledge, is probably the ﬁrst to attempt to estimate how
ILRs should be used in patients referred to Syncope Units.
Perspectives
Syncope Unit Project study
4 showed that syncope remained unex-
plained despite complete work-up in 18% of patients evaluated for
syncope in specialized Syncope Units. The patients referred to the
Syncope Unit are per se the most difﬁcult cases because they have
been selected from many others. The ﬁnding that patients poten-
tially at high risk remain without a diagnosis cannot be considered
satisfactory for a specialized facility and indicates the need for a
new management strategy. The present study shows that the ILR
is potentially indicated in two-thirds of these patients and that it
was greatly underutilized. The favourable observed diagnostic
yield of an ILR strategy suggests more extensive usage of this diag-
nostic tool.
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